|
43
|
111
|
7ushA |
Brd2-bd2 in complex with sf2523 |
|
39
|
109
|
7usjA |
Brd4-bd2 in complex with sf2523 |
|
41
|
127
|
7ruiA |
Bromodomain-containing protein 4 (brd4) bromodomain 1 (bd1) complexed with xr844 |
|
40
|
113
|
7ruhA |
Bromodomain-containing protein 4 (brd4) bromodomain 2 (bd2) complexed with xr844 |
|
46
|
128
|
7lzqA |
Crystal structure of the bcl6 btb domain in complex with oicr-4425 |
|
2
|
11
|
7xvyC |
Human estrogen receptor beta ligand-binding domain in complex with s-dpn |
|
84
|
236
|
7xvyA |
Human estrogen receptor beta ligand-binding domain in complex with s-dpn |
|
87
|
236
|
7xvzA |
Human estrogen receptor beta ligand-binding domain in complex with (r)-3-(2-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propanenitrile |
|
2
|
10
|
7xvzC |
Human estrogen receptor beta ligand-binding domain in complex with (r)-3-(2-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propanenitrile |
|
2
|
11
|
7xwpC |
Human estrogen receptor beta ligand-binding domain in complex with (s)-3-(2-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propanenitrile |
|
2
|
11
|
7xwqC |
Human estrogen receptor beta ligand-binding domain in complex with (r)-2-(2-chloro-4-hydroxyphenyl)-3-(4-hydroxyphenyl)propanenitrile |
|
88
|
236
|
7xwqA |
Human estrogen receptor beta ligand-binding domain in complex with (r)-2-(2-chloro-4-hydroxyphenyl)-3-(4-hydroxyphenyl)propanenitrile |
|
2
|
11
|
7xwrC |
Human estrogen receptor beta ligand-binding domain in complex with (s)-2-(2-chloro-4-hydroxyphenyl)-3-(4-hydroxyphenyl)propanenitrile |
|
87
|
236
|
7xwpA |
Human estrogen receptor beta ligand-binding domain in complex with (s)-3-(2-chloro-4-hydroxyphenyl)-2-(4-hydroxyphenyl)propanenitrile |
|
86
|
236
|
7xwrA |
Human estrogen receptor beta ligand-binding domain in complex with (s)-2-(2-chloro-4-hydroxyphenyl)-3-(4-hydroxyphenyl)propanenitrile |
|
43
|
118
|
7l9aA |
Crystal structure of brdt bromodomain 2 in complex with cdd-1102 |
|
1
|
12
|
6ultI |
Brd2-bd2 in complex with the cyclic peptide 4.2_3 |
|
1
|
14
|
6ulvE |
Brd4-bd1 in complex with the cyclic peptide 4.2_1 |
|
36
|
108
|
6ulvA |
Brd4-bd1 in complex with the cyclic peptide 4.2_1 |
|
0
|
14
|
6u8gE |
Brd4-bd2 in complex with the cyclic peptide 3.1_2_ack7toa |
|
0
|
14
|
6u74E |
Brd4-bd1 in complex with the cyclic peptide 3.1_2 |
|
42
|
127
|
6u72A |
Brd4-bd1 in complex with the cyclic peptide 3.1_2_ack5toa |
|
0
|
14
|
6u6lB |
Brd4-bd2 in complex with the cyclic peptide 3.1_2 |
|
0
|
11
|
6u4aC |
Brd3-bd1 in complex with the cyclic peptide 3.1_3 |
|
0
|
11
|
6u61D |
Brd2-bd1 in complex with the cyclic peptide 3.1_3 |
|
1
|
12
|
6u8hC |
Brd2-bd1 in complex with the cyclic peptide 3.2_2 |
|
38
|
118
|
6u61A |
Brd2-bd1 in complex with the cyclic peptide 3.1_3 |
|
41
|
120
|
6u4aA |
Brd3-bd1 in complex with the cyclic peptide 3.1_3 |
|
1
|
12
|
6u8iB |
Brd4-bd2 in complex with the cyclic peptide 3.2_2 |
|
0
|
17
|
6u8mC |
Brd4-bd1 in complex with the cyclic peptide 3.2_1 |
|
35
|
112
|
6u6lA |
Brd4-bd2 in complex with the cyclic peptide 3.1_2 |
|
41
|
126
|
6ulqA |
Brd2-bd1 in complex with the cyclic peptide 4.2_3 |
|
39
|
125
|
6u8mA |
Brd4-bd1 in complex with the cyclic peptide 3.2_1 |
|
33
|
110
|
6ulpA |
Brd3-bd2 in complex with the cyclic peptide 3.2_3 |
|
0
|
11
|
6u6kC |
Brd4-bd1 in complex with the cyclic peptide 3.1_3 |
|
39
|
126
|
6u8gA |
Brd4-bd2 in complex with the cyclic peptide 3.1_2_ack7toa |
|
4
|
15
|
6ulqD |
Brd2-bd1 in complex with the cyclic peptide 4.2_3 |
|
0
|
14
|
6u72C |
Brd4-bd1 in complex with the cyclic peptide 3.1_2_ack5toa |
|
43
|
126
|
6u6kA |
Brd4-bd1 in complex with the cyclic peptide 3.1_3 |
|
40
|
110
|
6u71A |
Brd2-bd2 in complex with the cyclic peptide 3.1_3 |
|
43
|
128
|
6u8hA |
Brd2-bd1 in complex with the cyclic peptide 3.2_2 |
|
0
|
11
|
6u71B |
Brd2-bd2 in complex with the cyclic peptide 3.1_3 |
|
42
|
128
|
6u74A |
Brd4-bd1 in complex with the cyclic peptide 3.1_2 |
|
38
|
109
|
6u8iA |
Brd4-bd2 in complex with the cyclic peptide 3.2_2 |
|
57
|
230
|
6uycA |
Crystal structure of tead2 bound to compound 2 |
|
102
|
311
|
6u6wA |
Discovery and optimization of salicyclic acid-derived sulfonamide inhibitors of the wdr5:myc protein-protein interaction |
|
39
|
115
|
6ddjA |
Crystal structure of the human brd2 bd2 bromodimain in complex with a tetrahydroquinoline analogue |
|
37
|
109
|
6db0A |
N-terminal bromodomain of human brd2 with a tetrahydroquinoline analogue |
|
40
|
115
|
6dbcA |
Second bromodomain of human brd2 with a tetrahydroquinoline analogue |
|
40
|
115
|
6ddiA |
Crystal structure of the human brd2 bd1 bromodomain in complex with a tetrahydroquinoline analogue |
